Voyage Medical, which is developing new treatment for a heart condition called atrial fibrillation, has raised $22 million in a second round of financing. New investor Three Arch Partners led the round, with participation from Kleiner Perkins Caulfield & Byers (also a new investor) and existing investor RWI Ventures, according to VentureWire.
Atrial fibrillation is a heart abnormality that affects 2.2 million Americans. Three Arch partner Bill Harrington told VentureWire that Voyage Medical's technique will improve on existing treatments because it allows doctors to perform "radiofrequency ablation" under direct visualization.
The Campbell, Calif. company previously raised $3.3 million in 2006.